Nikita Shrivastava
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nikita Shrivastava has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Priyank Bhargava
Department of Urology, All India Institute of Medical Sciences, Jodhpur, India
4 shared publications - Gautam Ram Choudhary
All India Institute of Medical Sciences Jodhpur, Jodhpur, India
3 shared publications - Gopal Sharma
Department of Urology, PGIMER, Chandigarh, India
2 shared publications - Arjun Singh Sandhu
All India Institute of Medical Sciences Jodhpur, Jodhpur, India
1 shared publication - Deepak Prakash Bhirud
Department of Urology, All India Institute of Medical Sciences (AIIMS), Jodhpur, India
1 shared publication Gautam Ram Chaudhary
Department of Urology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
1 shared publication
Latest Publications
- 27 July 2026
- Published by Springer Nature in Indian Journal of Surgical Oncology
- p. 1-12
Prostate Cancer Screening in the Era of Precision Medicine: A Narrative Review
- 27 July 2026
- Published by Springer Nature in Indian Journal of Surgical Oncology
- p. 1-12
Prostate Cancer Screening in the Era of Precision Medicine: A Narrative Review
- Open Access
- 1 October 2024
- Published by Medknow in Indian Journal of Urology
- Vol. 40 (4) , 285-286
Kidney-sparing management for high-risk upper tract urothelial carcinoma: Where do we stand?
- 1 October 2024
- Published by Medknow in Indian Journal of Urology
- Vol. 40 (4) , 285-286
Open AccessKidney-sparing management for high-risk upper tract urothelial carcinoma: Where do we stand?
- Open Access
- 1 July 2024
- Published by Wolters Kluwer Health in Indian Journal of Urology
- Vol. 40 (3) , 209-210
Re: Sharma AP, Singh PP, Chauhan R, Panda I, Devana SK, Bora GS, et al. Clinical study of steroid receptors in nonmuscle invasive bladder cancer: A domain worth revisiting. Indian J Urol 2024;40:127-32
- 1 July 2024
- Published by Wolters Kluwer Health in Indian Journal of Urology
- Vol. 40 (3) , 209-210
Open AccessRe: Sharma AP, Singh PP, Chauhan R, Panda I, Devana SK, Bora GS, et al. Clinical study of steroid receptors in nonmuscle invasive bladder cancer: A domain worth revisiting. Indian J Urol 2024;40:127-32
- 14 May 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-2
Reply to ‘Song Y, Jiang S, Yang W, Xu T. Letter to the editor for the article “Transperitoneal versus retroperitoneal robot-assisted partial nephrectomy: a systematic review and meta-analysis”. World J Urol. 2024 Apr 2;42(1):207.’
- 14 May 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-2
Reply to ‘Song Y, Jiang S, Yang W, Xu T. Letter to the editor for the article “Transperitoneal versus retroperitoneal robot-assisted partial nephrectomy: a systematic review and meta-analysis”. World J Urol. 2024 Apr 2;42(1):207.’
- 15 February 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-10
Transperitoneal versus retroperitoneal robot-assisted partial nephrectomy: a systematic review and meta-analysis
Introduction Robot-assisted partial nephrectomy (RAPN) can be performed either by a transperitoneal (TP) or a retroperitoneal (RP) approach. However, the superiority of one approach over the other is not established. Hence, the primary aim of this review was to compare perioperative outcomes between these two surgical approaches. Methods Literature was systematically searched to identify studies reporting perioperative outcomes following TP RAPN and RP RAPN. The study protocol was registered with PROSPERO (CRD42023399496). The primary outcome was comparing complication rates between the two approaches. Results This review included 22 studies, 5675 patients, 2524 in the RP group, and 3151 in the TP group. The overall complications were significantly lower in the RP group [Odds ratio (OR) 0.80 (0.67, 0.95), p = 0.01]. However, the rate of major complications was similar between the two groups. The operative time was significantly shorter with the RP group [Mean Difference (MD)—16.7 (− 22.3, − 11.0), p = < 0.0001]. Estimated blood loss (EBL) and need for blood transfusion (BT) were significantly lower in the RP group. There was no difference between the two groups for conversion to radical nephrectomy [OR 0.66 (0.33, 1.33), p = 0.25] or open surgery [OR 0.68 (0.24, 1.92, p = 0.47] and positive surgical margins [OR 0.93 (0.66, 1.31, p = 0.69]. Length of stay (LOS) was shorter in the RP group [MD − 0.27 (− 0.45, − 0.08), p = < 0.00001]. Conclusions RP approach, compared to TP, has significantly lower complication rates, EBL, need for BT and LOS. However, due to the lack of randomized studies on the topic, further data is required.
- 15 February 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-10
Transperitoneal versus retroperitoneal robot-assisted partial nephrectomy: a systematic review and meta-analysis
Introduction Robot-assisted partial nephrectomy (RAPN) can be performed either by a transperitoneal (TP) or a retroperitoneal (RP) approach. However, the superiority of one approach over the other is not established. Hence, the primary aim of this review was to compare perioperative outcomes between these two surgical approaches. Methods Literature was systematically searched to identify studies reporting perioperative outcomes following TP RAPN and RP RAPN. The study protocol was registered with PROSPERO (CRD42023399496). The primary outcome was comparing complication rates between the two approaches. Results This review included 22 studies, 5675 patients, 2524 in the RP group, and 3151 in the TP group. The overall complications were significantly lower in the RP group [Odds ratio (OR) 0.80 (0.67, 0.95), p = 0.01]. However, the rate of major complications was similar between the two groups. The operative time was significantly shorter with the RP group [Mean Difference (MD)—16.7 (− 22.3, − 11.0), p = < 0.0001]. Estimated blood loss (EBL) and need for blood transfusion (BT) were significantly lower in the RP group. There was no difference between the two groups for conversion to radical nephrectomy [OR 0.66 (0.33, 1.33), p = 0.25] or open surgery [OR 0.68 (0.24, 1.92, p = 0.47] and positive surgical margins [OR 0.93 (0.66, 1.31, p = 0.69]. Length of stay (LOS) was shorter in the RP group [MD − 0.27 (− 0.45, − 0.08), p = < 0.00001]. Conclusions RP approach, compared to TP, has significantly lower complication rates, EBL, need for BT and LOS. However, due to the lack of randomized studies on the topic, further data is required.
- 5 September 2023
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (17) , 15795-15804
Correlation between androgen and estrogen receptor expression and clinicopathologic features in carcinoma urinary bladder
Introduction The molecular mapping of cancers by the Cancer Genome Atlas Project has accelerated the quest for new therapeutic targets for urinary bladder cancer, including sex steroid receptors. Previous studies have demonstrated conflicting results on their relationship with bladder cancer, and there is sparse data on their expression in the Indian population. The aim of our study is to examine the expression of androgen receptors (AR) and estrogen receptors (ERα and ERβ) in patients with bladder cancer and their correlation with clinicopathologic features. Materials and methods In this retrospective cohort study, a total of 132 patients, who were surgically managed for urinary bladder mass by transurethral resection or radical cystectomy in our institute, with transitional cell carcinoma on histopathology and with at least two years of follow-up were included. Their demographic and treatment details were obtained, histopathology blocks were retrieved and immunohistochemical staining for androgen and estrogen receptors was performed. Then, the relationship between their expression and clinicopathologic features was studied. Results A total of 3.79% of patients showed estrogen receptor alpha positivity, 51.52% estrogen receptor beta positivity and 63.64% androgen receptor positivity. No statistically significant correlation was found between age of patients (p = 0.75/0.52/0.87), tumour stage and grade (0.71/0.3/0.21), pathological variant (p = 1/0.58/0.38) and overall survival (p = 0.70/0.052/0.45 for NMIBC and p = 0.82/0.36/0.22) and estrogen receptor alpha, estrogen receptor beta and androgen receptor-positive status, respectively. Estrogen receptor beta positivity was significantly higher in patients with unifocal (p = 0.015) and small tumours (< 5 cm) (p = 0.03), and its expression was associated with better disease-free survival (DFS) (p = 0.046) in patients of non-muscle invasive bladder cancer (NMIBC). Conclusion Our study has the largest sample size conducted on Indian population with results differing from previous studies conducted on western population. Estrogen receptor beta expression was significantly associated with small unifocal tumours and better DFS. Estrogen receptor alpha and androgen receptor expression were not found to be associated with the clinicopathologic features of the study population.
- 5 September 2023
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (17) , 15795-15804
Correlation between androgen and estrogen receptor expression and clinicopathologic features in carcinoma urinary bladder
Introduction The molecular mapping of cancers by the Cancer Genome Atlas Project has accelerated the quest for new therapeutic targets for urinary bladder cancer, including sex steroid receptors. Previous studies have demonstrated conflicting results on their relationship with bladder cancer, and there is sparse data on their expression in the Indian population. The aim of our study is to examine the expression of androgen receptors (AR) and estrogen receptors (ERα and ERβ) in patients with bladder cancer and their correlation with clinicopathologic features. Materials and methods In this retrospective cohort study, a total of 132 patients, who were surgically managed for urinary bladder mass by transurethral resection or radical cystectomy in our institute, with transitional cell carcinoma on histopathology and with at least two years of follow-up were included. Their demographic and treatment details were obtained, histopathology blocks were retrieved and immunohistochemical staining for androgen and estrogen receptors was performed. Then, the relationship between their expression and clinicopathologic features was studied. Results A total of 3.79% of patients showed estrogen receptor alpha positivity, 51.52% estrogen receptor beta positivity and 63.64% androgen receptor positivity. No statistically significant correlation was found between age of patients (p = 0.75/0.52/0.87), tumour stage and grade (0.71/0.3/0.21), pathological variant (p = 1/0.58/0.38) and overall survival (p = 0.70/0.052/0.45 for NMIBC and p = 0.82/0.36/0.22) and estrogen receptor alpha, estrogen receptor beta and androgen receptor-positive status, respectively. Estrogen receptor beta positivity was significantly higher in patients with unifocal (p = 0.015) and small tumours (< 5 cm) (p = 0.03), and its expression was associated with better disease-free survival (DFS) (p = 0.046) in patients of non-muscle invasive bladder cancer (NMIBC). Conclusion Our study has the largest sample size conducted on Indian population with results differing from previous studies conducted on western population. Estrogen receptor beta expression was significantly associated with small unifocal tumours and better DFS. Estrogen receptor alpha and androgen receptor expression were not found to be associated with the clinicopathologic features of the study population.